Bayer’s Asundexian Drug Reduces Stroke Risk by 26% in Study

Bayer AG’s experimental drug cut the risk of secondary strokes without increasing serious bleeding in a late-stage trial, bolstering its prospects of driving growth for the German company as it faces pressure from generic competition.

Asundexian reduced the chance of another stroke by 26% compared with placebo, when added to standard antiplatelet therapy such as Aspirin, Bayer said Thursday. The data adds to results released in November, and the company plans to submit the findings to regulators for approval.